Placenta Accreta SpectrumAdropinNCT07421180
Maternal Serum Adropin in Placenta Accreta Spectrum
An observational study of Placenta Accreta Spectrum and Placenta Previa, run by Adana City Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Placenta Accreta Spectrum, Placenta Previa
- How many people
- 84 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 May 2024to 1 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Pregnant women aged 18-45 years in the reproductive period with singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS were included in the study. The control group consisted of healthy pregnant women in the third trimester with similar demographic characteristics who underwent elective cesarean delivery and had no obstetric or medical comorbidities.
Who may be able to join
- Pregnant women aged 18-45 years in the reproductive period
- Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS
Who cannot join
- Uterine anomalies,
- Chronic systemic diseases,
- Multiple pregnancies,
- Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
University of Heath and Science Adana City Hospital
Adana, Yuregir, 01100
About this study
Official title: Maternal Serum Adropin as a Potential Biomarker for Placenta Accreta Spectrum
Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion.
Methods:
This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.
- Conditions
- Placenta Accreta Spectrum, Placenta Previa
- Keywords
- Placenta accreta spectrum, Placenta previa, Adropin, Endothelial dysfunction, Biomarker
- Medical subject headings
- Placenta Accreta, Placenta Previa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Study group (Diagnosed with Plasenta Previa and/or Placenta accreta spectrum) | Pregnant women aged 18-45 years viable third-trimester pregnancies diagnosed with placenta previa and/or PAS (Placenta accreta spectrum) | |
| control group | healthy pregnant women in the third trimester with similar demographic characteristics |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood serum Adropin levels
The aim of the present study was to evaluate maternal serum adropin levels in pregnancies complicated by placenta previa and placenta accreta spectrum and compare to healthy controls.
Measured: From 15.04.2024 to 01.04.2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2026
- Study start15 May 2024
- Primary completion1 Apr 2025
- Study completion1 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Placenta Accreta SpectrumStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Adana City Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gulsum Uysal, Adana City Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07421180
- Sponsor's protocol ID
- 79/25.07.2024
- Acronym
- Adropin
- Status last verified
- Feb 2026
- First submitted
- 12 Feb 2026
- Last updated
- 20 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Demographical values could be shared. The questionaries answers are personal so only scale results may be shown.
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Maternal Serum Adropin as a Potential Biomarker for Placenta Accreta Spectrum
- ClinicalTrials.gov ID
- NCT07421180
- Acronym / sponsor ID
- Adropin / 79/25.07.2024
- Conditions
- Placenta Accreta Spectrum, Placenta Previa
- Keywords
- Placenta accreta spectrum, Placenta previa, Adropin, Endothelial dysfunction, Biomarker
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- Adana City Training and Research HospitalUniversity, hospital or other
- Study start
- 15 May 2024 (actual)
- Primary completion
- 1 Apr 2025 (actual)
- Study completion
- 1 Apr 2025 (actual)
- First posted
- 19 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion.
Methods:
This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Study group (Diagnosed with Plasenta Previa and/or Placenta accreta spectrum) | – | –Pregnant women aged 18-45 years viable third-trimester pregnancies diagnosed with placenta previa and/or PAS (Placenta accreta spectrum) |
| control group | – | –healthy pregnant women in the third trimester with similar demographic characteristics |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Pregnant women aged 18-45 years in the reproductive period with singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS were included in the study. The control group consisted of healthy pregnant women in the third trimester with similar demographic characteristics who underwent elective cesarean delivery and had no obstetric or medical comorbidities.
Key inclusion criteria (2 listed)
- Pregnant women aged 18-45 years in the reproductive period
- Singleton, viable third-trimester pregnancies diagnosed with placenta previa and/or PAS
Key exclusion criteria (4 listed)
- Uterine anomalies,
- Chronic systemic diseases,
- Multiple pregnancies,
- Obstetric complications such as preterm premature rupture of membranes, threatened preterm labor, fetuses followed for intrauterine growth restriction, and placental abruption.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Blood serum Adropin levels
Time frame: From 15.04.2024 to 01.04.2025
The aim of the present study was to evaluate maternal serum adropin levels in pregnancies complicated by placenta previa and placenta accreta spectrum and compare to healthy controls.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2026.
- Individual participant dataSharing planned: No. Demographical values could be shared. The questionaries answers are personal so only scale results may be shown.
Related trials for Placenta Accreta Spectrum
Not yet recruitingObservational study
Placenta-Cervical Interface Angle for Predicting Placenta Accreta Spectrum Severity
Placenta Accreta Spectrum, Placenta Previa
Not yet recruitingObservational study
Hematological and Coagulation Markers in Predicting Placenta Accreta Spectrum in Placenta Previa
Placenta Accreta Spectrum, Placenta Previa
Not yet recruitingObservational study
Ultrasound Scoring System for Diagnosis and Prediction of Severity and Surgical Outcomes of Placenta Accreta Spectrum
Placenta Accreta, Third Trimester
Not yet recruitingObservational study
Total Lower Uterine Segmentectomy With Adjunctive Mechanical Towel Compression for the Surgical Management of Placenta Accreta Spectrum Disorders
Placenta Accreta Management
Recruiting
Comparison Between 3 Conservative Surgeries for Placenta Accreta Spectrum
Placenta Accreta Spectrum
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Placenta Accreta Spectrum and Placenta Previa, run by Adana City Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood serum Adropin levels (time frame: From 15.04.2024 to 01.04.2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.